In a phase Ia/b trial from 2020 called JVDJ, the safety and efficacy of ramucirumab, a fully humanized IgG1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2 (VEGFR2), and durvalumab, a PD-L1 inhibitor, for patients with non-small cell lung cancer, G/GEJ adenocarcinoma and hepatocellular carcinoma (HCC) were studied (Table 2) [44]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.